natgillin/translations-raw huggingface dataset:
Patients treated with Kuvan must continue a restricted phenylalanine diet and undergo regular clinical assessment (such as monitoring of blood phenylalanine and tyrosine levels, nutrient intake, and psycho- motor development).
Bolniki, ki se zdravijo z zdravilom Kuvan, morajo nadaljevati s prehrano z omejenim vnosom fenilalanina, potrebujejo pa tudi redni klinični nadzor (kot je spremljanje ravni fenilalanina in tirozina v krvi, vnos hranil in psihomotorični razvoj).
Patients treated with LEMTRADA are also at a higher risk of developing listeriosis/Listeria meningitis.
Bolniki, ki se zdravijo z zdravilom LEMTRADA, imajo večje tveganje za razvoj listerioze/listerijskega meningitisa (bakterijska okužba, do katere pride z uživanjem okužene hrane).
Patients treated with Lemtrada are at a higher risk of developing herpes infection (e.g. a cold sore).
Bolniki, ki se zdravijo z zdravilom LEMTRADA, imajo večje tveganje za razvoj herpesne okužbe (npr. herpes na ustnicah).
Patients treated with LEMTRADA are at a higher risk of getting a serious infection (see section 4 – infections).
Pri bolnikih, ki se zdravijo z zdravilom LEMTRADA, je večje tveganje za resne okužbe (glejte poglavje 4
Patients treated with LEMTRADA must be given the Package Leaflet, the Patient Alert Card and the Patient Guide.
Bolniki, ki se zdravijo z zdravilom LEMTRADA, morajo prejeti navodilo za uporabo, opozorilno kartico bolnika in vodič za bolnike.
Patients treated with liraglutide had a significant decrease in body weight compared to that of patients treated with sitagliptin (­2.9 kg and ­3.4 kg vs ­1.0 kg, p0.0001).
Bolnikom, ki so prejemali liraglutid, se je telesna masa značilno bolj znižala kot bolnikom, ki so prejemali sitagliptin (-2,9 kg in -3,4 kg v prim. z -1,0 kg, p  0,0001).
Patients treated with lomitapide should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.
Bolnike, ki se zdravijo z lomitapidom, je treba seznaniti z možnim tveganjem za dehidracijo v povezavi z gastrointestinalnimi neželenimi učinki in s previdnostnimi ukrepi za preprečitev izgube tekočine.
Patients treated with lumacaftor/ivacaftor for 24 weeks in Trial 1 or Trial 2 continued to show improvements in BMI after an additional 24 weeks.
Bolniki, 24 tednov zdravljeni z lumakaftorjem/ivakaftorjem v preskušanju 1 ali preskušanju 2, so po dodatnih 24 tednih še naprej kazali izboljšanja ITM.
Patients treated with Lyxumia should be advised of the potential risk of dehydration in relation to gastrointestinal adverse reactions and take precautions to avoid fluid depletion.
Bolnike, ki prejemajo zdravilo Lyxumia, je treba seznaniti z možnim tveganjem za dehidracijo, povezano s neželenimi učinki v prebavilih; naročiti jim je treba, naj upoštevajo previdnostne ukrepe za preprečitev pomanjkanja tekočine.
Patients treated with MabThera in combination with methotrexate had a significantly greater reduction in disease activity score (DAS28) than patients treated with methotrexate alone (Table 9).
V vseh študijah je bilo pri bolnikih, ki so se zdravili z zdravilom MabThera in metotreksatom, zmanjšanje aktivnosti bolezni (DAS28, Disease Activity Score) pomembno večje kot pri bolnikih, ki so se zdravili samo z metotreksatom (preglednica 9).
Patients treated with MabThera must be given the patient alert card with each infusion.
Bolniku je treba ob vsaki infuziji zdravila MabThera dati kartico za bolnike.
Patients treated with MabThera must be given the patient alert card with each infusion.
Bolniku je treba ob vsaki infuziji zdravila MabThera dati opozorilno izkaznico.
Patients treated with myeloablative therapy followed by bone marrow transplantation
Bolniki, zdravljeni z mieloablativno terapijo, ki ji sledi presaditev kostnega mozga
Patients treated with OZURDEX who have experienced an initial response and in the physician’s opinion may benefit from retreatment without being exposed to significant risk should be considered for retreatment.
Pri bolnikih, zdravljenih z zdravilom OZURDEX, ki so se odzvali na prvo zdravljenje in za katere zdravnik meni, da bi jim ponovno zdravljenje koristilo, ne da bi bili pri tem izpostavljeni znatnemu tveganju, se lahko izvede ponovno zdravljenje.
Patients treated with Remicade should be given the package leaflet and the special Alert card.
Bolniki, zdravljeni z zdravilom Remicade, pa morajo dobiti Navodilo za uporabo in posebno opozorilno kartico.
Patients treated with Remsima should be given the package leaflet and the special Alert card.
Bolniki, zdravljeni z zdravilom Remsima, pa morajo dobiti Navodilo za uporabo in posebno opozorilno kartico.
Patients treated with Simponi may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6).
Bolniki, zdravljeni z zdravilom Simponi, so lahko sočasno cepljeni, razen z živimi cepivi (glejte poglavji 4.5 in 4.6).
Patients treated with Simponi must also be given a special alert card that summarises the safety information about the medicine.
Bolniki, ki prejmejo zdravilo Simponi, morajo dobiti posebno opozorilno kartico s povzetkom informacij o varnosti zdravila.
Patients treated with Simponi should be given the Patient Alert Card.
Bolniki, zdravljeni z zdravilom Simponi, morajo dobiti opozorilno kartico za bolnike.
Patients treated with sitagliptin exhibited a significant mean decrease from baseline in body weight (-1.5 kg) compared to a significant weight gain in patients administered glipizide (+1.1 kg).
Pri bolnikih, ki so prejemali sitagliptin, so opazili pomembno povprečno zmanjšanje telesne mase glede na začetno vrednost (–1,5 kg) v primerjavi s pomembnim povečanjem telesne mase pri bolnikih, ki so prejemali glipizid (+1,1 kg).
Patients treated with Stivarga lived on average for 147 days without their disease getting worse compared with 28 days for patients taking placebo and supportive care.
Bolniki, ki so bili zdravljeni z zdravilom Stivarga, so v povprečju živeli 147 dni brez poslabšanja bolezni v primerjavi z 28 dnevi pri bolnikih, ki so prejemali placebo in podporno oskrbo.
Patients treated with tacrolimus have been reported to develop EBV-associated lymphoproliferative disorders (see section 4.8).
Pri bolnikih, ki so se zdravili s takrolimusom, so poročali o pojavu z Epstein-Barr virusom (EBV) povezanih limfoproliferativnih boleznih (glejte poglavje 4.8).
Patients treated with tacrolimus have been reported to develop Epstein-Barr Virus (EBV(-associated lymphoproliferative disorders (see section 4.8).
Pri bolnikih, ki so se zdravili s takrolimusom, so poročali o pojavu z Epstein-Barr virusom (EBV) povezanih limfoproliferativnih bolezni (glejte poglavje 4.8).
Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES).
Poročali so, da se je pri bolnikih, ki se zdravijo s takrolimusom, razvil posteriorni reverzibilni encefalopatični sindrom ("posterior reversible encephalopathy syndrome" (PRES)).
Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES).
Poročali so, da se je pri bolnikih, ki se zdravijo s takrolimusom, razvil posteriorni reverzibilni encefalopatični sindrom (PRES).
Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES).
Pri bolnikih, zdravljenih s takrolimusom, so poročali o razvoju posteriornega reverzibilnega encefalopatičnega sindroma (PRES).
Patients treated with tasimelteon experienced an overall improvement in clinical global functioning (CGI- C = 2.6) as compared to patients treated with placebo who showed no improvement status (CGI-C = 3.4) compared to the severity of Non-24 at baseline (LS mean difference = -0.8; p=0.0093) (Table 4).
Pri bolnikih, zdravljenih s tasimelteonom, so opazili splošno izboljšanje splošnega delovanja po kliničnih merilih (CGI-C = 2,6) v primerjavi z bolniki, zdravljenimi s placebom, pri katerih niso opazili nobenega izboljšanja (CGI-C = 3,4) glede na resnost ne-24-urnega ciklusa ob izhodišču (povprečna razlika najmanjših kvadratov = –0,8; p = 0,0093) (preglednica 4).
Patients treated with TCF had a longer time to 5% definitive deterioration of global health status on the QLQ-C30 questionnaire (p=0.0121) and a longer time to definitive worsening of Karnofsky performance status (p=0.0088) compared to patients treated with CF.
Pri bolnikih, zdravljenih s TCF, je bil v primerjavi s tistimi, ki so jih zdravili s CF, daljši tako čas do 5 % trajnega poslabšanja splošnega zdravstvenega stanja po vprašalniku QLQ-C30 (p = 0,0121) kot čas do trajnega poslabšanja indeksa zmogljivosti po Karnofskem (p = 0,0088).
Patients treated with this medicine should be monitored for possible clinical immunological reactions.
Bolnike, zdravljene s tem zdravilom, je treba nadzorovati za morebitne klinične imunološke reakcije.
Patients treated with TMZ may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome.
Pri bolnikih, zdravljenih s TMZ lahko pride do mielosupresije , vključno s podaljšano pancotopenijo, kar lahko povzroči aplastično anemijo, ki se je v nekaterih primerih končala s smrtnim izidom.
Patients treated with trastuzumab emtansine should have HER2 positive tumour status, defined as a score of 3 + by immunohistochemistry (IHC) or a ratio of ≥ 2.0 by in situ hybridization (ISH) assessed by a CE-marked In Vitro Diagnostic (IVD) medical device.
Bolniki, zdravljeni s trastuzumabom emtanzinom, morajo imeti HER2-pozitivni tumor, imunohistokemično opredeljen kot 3+ ali razmerje pri in situ hibridizaciji (ISH) > 2,0, določeno z validiranim testom (z diagnostičnim medicinskim pripomočkom in vitro z oznako CE).
Patients treated with ustekinumab received 45 mg or 90 mg at Weeks 0 and 4 (dosed by weight as per approved posology)
Bolniki, ki so prejemali ustekinumab, so v tednih 0 in 4 prejeli odmerek 45 mg ali 90 mg (glede na telesno maso v skladu z odobrenim odmerjanjem).
Patients treated with Vargatef have an increased risk of venous thromboembolism including deep vein thrombosis.
Pri bolnikih, zdravljenih z zdravilom Vargatef, je povečano tveganje za vensko trombembolijo, vključno z globoko vensko trombozo.
Patients treated with XELIRI experienced excessive gastrointestinal toxicity compared with FOLFIRI (diarrhoea 48% and 14% for XELIRI and FLFIRI respectively).
Bolniki, zdravljeni s XELIRI, so imeli več gastrointestinalnih toksičnosti v primerjavi z bolniki, zdravljenimi s FOLFIRI (driska 48 % za XELIRI in 14 % za FOLFIRI).
Patients treated with XGEVA should be given the package leaflet and the patient reminder card.
Bolniki, zdravljeni z zdravilom XGEVA, morajo dobiti navodilo za uporabo in opozorilno kartico za bolnika.
Patients treated with Zerit have reported the following side effects: Common (may affect up to 1 in 10 people)
Pri bolnikih, ki se zdravijo z zdravilom Zerit, so poročali o naslednjih neželenih učinkih: Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
Patients treated with Zinbryta should be advised to report any symptoms of new or worsening depression, and/or suicidal ideation to the prescribing physician.
Bolnike, ki se zdravijo z zdravilom Zinbryta, je treba opozoriti, da morajo poročati o vseh novih ali poslabšanih simptomih depresije in/ali samomorilnih mislih zdravniku, ki je zdravilo predpisal.
Patients unable to follow or comply with the required contraceptive measures (see section 4.4).
Bolnice, ki niso sposobne slediti kontracepcijskim ukrepom ali se ravnati v skladu z njimi (glejte poglavje 4.4.).
patients under the age of 6), at
bolnike, mlajše od 6 let),
patients under the age of 6), at
za bolnike, mlajše od 6 let),
Patients undergoing acute alcohol or benzodiazepine withdrawal
Bolniki, ki prestajajo akutno odtegnitev alkohola ali benzodiazepinov
Patients undergoing chemotherapy and/or radiotherapy, are taking steroids or anti-angiogenic medicines (used to treat cancer), undergoing dental surgery, who do not receive routine dental care or have gum disease, are smokers may have a higher risk of developing osteonecrosis of the jaw.
Bolniki, ki prejemajo kemoterapijo in/ali radioterapijo, jemljejo steroide ali antiangiogena zdravila (uporabljajo se za zdravljenje raka), imajo zobozdravstven kirurški poseg, niso deležni redne zobozdravstvene oskrbe ali imajo bolezen dlesni, so kadilci, imajo lahko večje tveganje za nastanek osteonekroze čeljustnice.
Patients undergoing hip or knee replacement surgery and patients with atrial fibrillation, DVT, pulmonary embolism or who have had acute coronary syndrome are at a risk of blood clots forming or re-occuring and moving to another part of the body.
Pri bolnikih po kirurški zamenjavi kolka ali kolena in bolnikih z atrijsko fibrilacijo, DVT, pljučno embolijo ali tistih, ki so doživeli akutni koronarni sindrom, obstaja tveganje za nastanek ali ponovni pojav krvnih strdkov, ki se lahko premaknejo v drugi del telesa.
Patients undergoing hip or knee replacement surgery, who have had a recent trauma, or are confined to bed are at a high risk of blood clots forming in the veins, which can be dangerous and even fatal if they move to another part of the body such as the lungs.
Pri bolnikih, ki so jim operativno vstavili umetni kolk ali koleno, ki so se pred kratkim poškodovali ali so priklenjeni na posteljo, obstaja veliko tveganje za nastanek krvnih strdkov v venah, ki so lahko nevarni ali celo smrtni, če se premaknejo v drug del telesa, kot so npr. pljuča.
Patients undergoing major orthopaedic or abdominal surgery
Bolniki z večjimi ortopedskimi ali abdominalnimi operacijami
Patients undergoing major orthopaedic or abdominal surgery
Bolniki z večjimi ortopedskimi ali abdominalnimi operacijami.
Patients undergoing major surgery may be treated for up to 2 – 3 weeks until healing has occurred.
Bolniki, ki so prestali večjo operacijo, lahko zdravilo dobivajo od 2 do 3 tedne, dokler ni končano celjenje.
Patients undergoing ovarian stimulation are at an increased risk of developing OHSS due to multiple follicular development.
Pri bolnicah, ki so v postopku stimulacije jajčnikov, je povečano tveganje za razvoj OHSS zaradi razvoja več foliklov.
Patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI
Bolniki, pri katerih se bo izvedla PCI, vključno z bolniki z miokardnim infarktom z zvišanjem intervala ST (STEMI), pri katerih se bo izvedla primarna PCI
Patients up-titrated to 150 mg Q2W had a higher mean baseline LDL-C.
Bolniki, ki jim je bil odmerek povečan na 150 mg na 2 tedna, so imeli izhodiščno višji LDL-H.
Patients using
posebno
Patients using clarithromycin at
Pri bolnikih z ledvično
Patients using GANFORT with other prostaglandin analogs should be monitored for changes to their intraocular pressure.
Pri bolnikih, ki uporabljajo zdravilo GANFORT skupaj z drugimi analogi prostaglandina, je treba spremljati spremembe očesnega tlaka.
Patients using inhaled steroids
Bolniki, ki uporabljajo inhalacijske steroide
Patients using oestrogens
Bolnike, ki uporabljajo
Patients using oestrogens as hormone
Bolnice, ki jemljejo estrogene v okviru
patients weighing 50 kg or
ali več je pri jemanju z
Patients weighing < 60 kg
Bolniki, ki tehtajo < 60 kg
Patients weighing < 60 kg should have a reduced maintenance dose of 5mg
Bolniki s telesno maso < 60 kg morajo jemati nižji vzdrževalni odmerek 5 mg.
Patients were 3–17 years of age with active polyarticular course JRA regardless of onset type and naive to methotrexate or leflunomide.
Bolniki so bili stari od 3 do 17 let, imeli so aktiven JRA s poliartikularnim potekom, ne glede na način pojava, in še niso dobivali metotreksata ali leflunomida.
Patients were 6 - 18 years and presented an average score of 29 on TTS-YGTSS at baseline.
Bolniki so bili stari od 6 do 18 let, njihov izhodiščni rezultat na lestvici TTS- YGTSS pa je bil 29.
Patients were administered either the tablet or the soft capsule formulation for 8 weeks, after which all patients were administered the tablet formulation once daily or twice daily for the remainder of the study.
Bolniki so 8 tednov dobivali bodisi tablete bodisi mehke kapsule; po tem obdobju so vsi bolniki med preostalim obdobjem študije dobivali tablete enkrat na dan ali dvakrat na dan.
Patients were administered emtricitabine 200 mg once daily and tenofovir DF 300 mg once daily.
Bolniki so dobivali emtricitabin 200 mg enkrat na dan in tenofovir DF 300 mg enkrat na dan.
Patients were administered intravenous doses of 0.7 to 1.3 mg/m2 of VELCADE twice weekly.
Bolniki so dvakrat na teden prejemali intravenske odmerke zdravila VELCADE v odmerku od 0,7 do 1,3 mg/m2.
Patients were also excluded if they had experienced any of: an ATE, Grade 4 hypertension, Grade 3 proteinuria, a grade 3-4 bleeding event, or bowel perforation during first-line bevacizumab therapy.
Bolniki so bili izključeni tudi, če je pri njih prišlo do katerega koli izmed naslednjih dogodkov: arterijski trombotski dogodek, hipertenzija stopnjer 4, proteinurija stopnje 3, krvavitev 3–4 ali perforacija prebavil med zdravljenjem prve izbire z bevacizumabom.
Patients were also randomised to receive placebo at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Bolniki, ki so bili randomizirani na prejemanje placeba, so tega prejeli v tednih 0, 1, 2 in 3, nato pa enak odmerek enkrat na mesec z začetkom v tednu 4.
Patients were also required to have an inadequate response or intolerance to two or more NSAIDs.
Bolniki so morali imeti tudi nezadostni odziv na vsaj dva NSAID ali intoleranco zanju.
Patients were also required to have documented confirmation of the presence of a nonsense mutation in the dystrophin gene as determined by gene sequencing.
Prav tako so bolniki morali imeti potrdilo o prisotnosti nesmiselne mutacije gena za distrofin, ki je bila ugotovljena s sekvenciranjem genov.
Patients were at least 12 years of age and had a diagnosis of PAH that was idiopathic, related to collagen disease, related to anorexigen use, related to human immunodeficiency virus (HIV) infection, associated with an atrial-septal defect, or associated with surgical repair of at least 1 year in duration of a congenital systemic-to-pulmonary shunt (for example, ventricular septal defect, patent ductus arteriosus).
Bolniki so bili stari vsaj 12 let in so bili diagnosticirani s PAH, ki je bila idiopatska, povezana s sistemsko boleznijo veziva, povezana z uporabo anoreksigena, povezana z okužbo s človeškim virusom imunske pomanjkljivost (HIV), povezana z atrialno-septalno okvaro ali manj kot eno leto po kirurški popravi kongenitalnega sistemsko-pljučnega šunta (npr. ventrikularna septalna okvara, patent ductus arteriosus).
Patients were between 18 and 70 years of age and had active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis- like ankylosis.
Starost bolnikov je bila od 18 do 70 let in vsi so imeli aktivni psoriatični artritis (≥ 3 otekli sklepi in ≥ 3 občutljivi sklepi) v najmanj eni od naslednjih oblik: (1) distalna interfalangealna prizadetost (DIP); (2) poliartikularni artritis (odsotnost revmatoidnih nodulov in prisotnost psoriaze); (3) artritis mutilans; (4) asimetrični psoriatični artritis ali (5) spondilitisu podobna ankiloza.
Patients were between 18 and 70 years of age and had active psoriatic arthritis ( 3 swollen joints and  3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis- like ankylosis.
Starost bolnikov je bila od 18 do 70 let in vsi so imeli aktivni psoriatični artritis (≥ 3 otekli sklepi in ≥ 3 občutljivi sklepi) v najmanj eni od naslednjih oblik: (1) distalna interfalangealna prizadetost (DIP); (2) poliartikularni artritis (odsotnost revmatoidnih nodulov in prisotnost psoriaze); (3) artritis mutilans; (4) asimetrični psoriatični artritis ali (5) spondilitisu podobna ankiloza.
Patients were between 18 and 70 years of age and had active psoriatic arthritis ( 3 swollen joints and  3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis-like ankylosis.
Starost bolnikov je bila od 18 do 70 let in vsi so imeli aktivni psoriatični artritis (≥ 3 otekli sklepi in ≥ 3 občutljivi sklepi) v najmanj eni od naslednjih oblik: (1) distalna interfalangealna prizadetost (DIP); (2) poliartikularni artritis (odsotnost revmatoidnih nodulov in prisotnost psoriaze); (3) artritis mutilans; (4) asimetrični psoriatični artritis ali (5) spondilitisu podobna ankiloza.
Patients were classified as having experienced no significant worsening of vision if the number of letters that they could see increased, stayed the same, or fell by less than 15.
Če se je število črk, ki jih je bolnik lahko videl, povečalo, ostalo enako ali zmanjšalo za manj kot 15, je bilo ocenjeno, da se mu vid ni bistveno poslabšal.
Patients were considered to have impaired bone marrow reserve if they had any of the following: prior myeloablative therapy with stem cell support; prior external beam radiation to >25% of active marrow; a platelet count <100,000 cells/mm3; or neutrophil count <1,500 cells/mm3.
Veljalo je, da so imeli bolniki prizadeto rezervo kostnega mozga, če so imeli kaj od naslednjega: predhodno ablacijo kostnega mozga s podporo matičnih celic; predhodno obsevanje, ki je zajelo več kot 25 % delujočega kostnega mozga; število trombocitov < 100.000 celic/mm3; število nevtrofilnih celic < 1.500 celic/mm3.
Patients were considered to have responded to treatment if, on at least three out of four occasions, their walking speed was faster than their highest speed before treatment.
Kot bolniki, ki so se odzvali na zdravljenje, so se šteli tisti bolniki, pri katerih je bila hitrost hoje vsaj v treh od štirih primerov višja od najvišje hitrosti hoje pred zdravljenjem.
Patients were either HBV-treatment-naïve or pretreated (excluding pretreatment with entecavir, adefovir dipivoxil, or tenofovir disoproxil fumarate).
Bolniki se zaradi okužbe z virusom HBV predhodno še niso ali pa so se zdravili (vendar pa ne z entekavirjem, adefovirdipivoksilom ali tenofovirdizoproksil fumaratom).
Patients were either naïve to Herceptin IV treatment (20.3%) or pre- exposed to Herceptin IV (79.7%).
Bolniki še niso prejemali zdravila Herceptin v intravenski obliki (20,3 %) ali pa so bili predhodno izpostavljeni zdravilu Herceptin v intravenski obliki (79,7 %).
Patients were either previously untreated or receiving treatment with other PAH medicines (ERA or PDE-5 inhibitors).
Bolniki pred tem niso bili zdravljeni ali pa so bili zdravljeni z drugimi zdravili za PAH (ERA ali zaviralci FDE-5).
Patients were eligible for the RELY-ABLE trial if they had not permanently discontinued study medication at the time of their final RE-LY study visit.
Merila za vključitev v raziskavo RELY-ABLE so izpolnjevali bolniki, ki do zadnjega kontrolnega obiska v raziskavi RE-LY niso trajno prekinili zdravljenja s preizkušanim zdravilom.
Patients were eligible to participate if they were aged 50 years or over, with a history of MI (1 to 3 years prior to randomisation), and had at least one of the following risk factors for atherothrombosis: age ≥65 years, diabetes mellitus requiring medication, a second prior MI, evidence of multivessel CAD, or chronic non-end-stage renal dysfunction.
Za sodelovanje so bili primerni bolniki, stari 50 let ali več, z anamnezo miokardnega infarkta (od 1 do 3 leta pred randomizacijo) in vsaj enim od naslednjih dejavnikov tveganja za aterotrombozo: starost ≥ 65 let, sladkorna bolezen, ki zahteva zdravila, drugi predhodni miokardni infarkt, znaki večžilne bolezni koronarnih arterij ali kronično moteno delovanje ledvic, ki ni v končni fazi.